Generex Biotech and Avanir Pharmaceuticals Look to Rally in 2012
The Paragon Report Provides Equity Research on Generex Biotechnology & Avanir Pharmaceuticals
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 12/12/11 -- The biotechnology industry has been a strong performer in 2011 as mergers and acquisitions and favorable legislation have propped up the sector. The domestic biotechnology industry has tapped into only a fraction of its several potential applications and is expected to grow to $146.2 billion in 2016, from an estimated $92.4 billion in 2011, according to a report from IBISWorld. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Generex Biotechnology Corporation (OTCBB: GNBT) and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Access to the full company reports can be found at:
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. Last month the company announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application for NUEDEXTA for the treatment of pseudobulbar affect (PBA).
NUEDEXTA was approved by the U.S. Food and Drug Administration in October 2010 for the treatment of PBA, a neurologic condition which is characterized by frequent outbursts of involuntary crying or laughing.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at and get exclusive access to our numerous stock reports and industry newsletters.
Generex Biotechnology Corporation is a development stage company engaged in the research and development of drug delivery systems and technologies for metabolic and immunological diseases. Last week shares of the company spiked after it announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR.
Generex explains that its Ii-Key Hybrid technology platform entails the modification of fragments of antigens to increase their potency in stimulating critical members of the immune response, known as CD4+ T helper cells.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 12.12.2011 - 13:16 Uhr
Sprache: Deutsch
News-ID 95869
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Commercial & Investment Banking
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Generex Biotech and Avanir Pharmaceuticals Look to Rally in 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Paragon Financial Limited (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
